Integrum AB (OSTO:INTEG B) FCF Margin % : -16.16% (As of Jan. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Integrum AB FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Integrum AB's Free Cash Flow for the three months ended in Jan. 2024 was kr-4.87 Mil. Integrum AB's Revenue for the three months ended in Jan. 2024 was kr30.11 Mil. Therefore, Integrum AB's FCF Margin % for the quarter that ended in Jan. 2024 was -16.16%.

As of today, Integrum AB's current FCF Yield % is -1.99%.

The historical rank and industry rank for Integrum AB's FCF Margin % or its related term are showing as below:

OSTO:INTEG B' s FCF Margin % Range Over the Past 10 Years
Min: -118.36 Med: -49.14 Max: -4.47
Current: -20.82

During the past 9 years, the highest FCF Margin % of Integrum AB was -4.47%. The lowest was -118.36%. And the median was -49.14%.

OSTO:INTEG B's FCF Margin % is ranked worse than
60.84% of 830 companies
in the Medical Devices & Instruments industry
Industry Median: -7.41 vs OSTO:INTEG B: -20.82

Integrum AB FCF Margin % Historical Data

The historical data trend for Integrum AB's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integrum AB FCF Margin % Chart

Integrum AB Annual Data

Trend

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

FCF Margin %

Get a 7-Day Free Trial

-113.45

-71.28

-15.66

-88.92

-49.14

Integrum AB Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
FCF Margin %	Get a 7-Day Free Trial															-37.72	-39.28	-57.29	13.23	-16.16

Competitive Comparison of Integrum AB's FCF Margin %

For the Medical Devices subindustry, Integrum AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Integrum AB's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Integrum AB's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Integrum AB's FCF Margin % falls into.

Integrum AB FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Integrum AB's FCF Margin for the fiscal year that ended in Apr. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Apr. 2023 )	/	Revenue (A: Apr. 2023 )
	=	-36.5	/	74.272
	=	-49.14 %

Integrum AB's FCF Margin for the quarter that ended in Jan. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jan. 2024 )	/	Revenue (Q: Jan. 2024 )
	=	-4.865	/	30.108
	=	-16.16 %

Integrum AB FCF Margin % Related Terms

Thank you for viewing the detailed overview of Integrum AB's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Integrum AB (OSTO:INTEG B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Integrum AB (OSTO:INTEG B) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

6Y1:Germany

Address

Krokslatts Fabriker 50, Molndal, SWE, SE-431 37

Website

http://www.integrum.se

Integrum AB provides the system for bone-anchored prostheses that improves the lives of people with amputations. Its solutions include OPRA implant system, Neural prosthetics, Phantom limb pain treatment, and Prosthetic components. The company is also engaged in developing technology for mind-controlled prostheses and treatment for phantom limb pain.

Integrum AB (OSTO:INTEG B) Headlines

No Headlines